Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Cullinan Management ( (CGEM) ) just unveiled an update.
On June 4, 2025, Cullinan Therapeutics entered into a global license agreement with Chongqing Genrix Biopharmaceutical to develop and commercialize velinotamig, a BCMAxCD3 bispecific T cell engager, in autoimmune diseases outside Greater China. The agreement involves an upfront payment of $20 million, with potential milestone payments and royalties based on sales. This strategic move enhances Cullinan’s portfolio, allowing it to address a broader range of autoimmune diseases and maintain its cash runway into 2028. Genrix will conduct a Phase 1 study in China, with Cullinan planning to use the data to accelerate global clinical development.
The most recent analyst rating on (CGEM) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Cullinan Management stock, see the CGEM Stock Forecast page.
Spark’s Take on CGEM Stock
According to Spark, TipRanks’ AI Analyst, CGEM is a Underperform.
Cullinan Management’s stock is facing significant challenges primarily due to its weak financial performance, characterized by persistent losses and negative cash flow. The technical analysis provides some short-term optimism, but the overall technical outlook remains bearish. The valuation is unattractive due to a negative P/E ratio and no dividend yield, indicating high risk for investors. The stock’s potential is heavily reliant on strategic changes and improved financial health.
To see Spark’s full report on CGEM stock, click here.
More about Cullinan Management
Cullinan Therapeutics, Inc. is a biopharmaceutical company focused on developing modality-agnostic targeted therapies for autoimmune diseases and cancer. The company has a diversified portfolio of clinical-stage assets aimed at inhibiting key drivers of disease or harnessing the immune system to eliminate diseased cells. Cullinan is committed to creating new standards of care for patients, leveraging its deep understanding of oncology, immunology, and translational medicine.
Average Trading Volume: 456,115
Technical Sentiment Signal: Sell
Current Market Cap: $516.4M
See more insights into CGEM stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue